Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 3/20 | 0.39 |
| ▸ | PNMT | P11086 | 1/20 | 0.36 |
| ▸ | ADRB3 | P13945 | 7/20 | 0.35 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.35 |
| ▸ | TACR1 | P25103 | 2/20 | 0.34 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.33 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5754070 | 0.85 | SLC2A1 (0.43) | SLC2A1PNMTADRB3ADRB1ADRB2 | |
| SCHEMBL5751830 | 0.82 | ADRB3 (0.42) | SLC2A1ADRB3ADRB1ADRB2ADRA1D | |
| SCHEMBL5753866 | 0.81 | SLC2A1 (0.42) | SLC2A1PNMTADRB3ADRB1ADRB2 | |
| SCHEMBL5753904 | 0.80 | SLC2A1 (0.43) | SLC2A1PNMTADRB3ADRB1ADRB2 | |
| SCHEMBL5753171 | 0.79 | ADRB3 (0.40) | SLC2A1ADRB3ADRB1ADRB2ADRA1D | |
| SCHEMBL7157741 | 0.79 | ADRB3 (0.40) | SLC2A1ADRB3ADRB1ADRB2ADRA1D | |
| SCHEMBL5752334 | 0.77 | SLC2A1 (0.46) | SLC2A1ADRB3ADRB1ADRB2ADRA1D | |
| SCHEMBL5750724 | 0.77 | SLC2A1 (0.40) | SLC2A1PNMTADRB3ADRB1ADRB2 | |
| SCHEMBL5750415 | 0.74 | CETP (0.44) | — | |
| SCHEMBL5751748 | 0.73 | PNMT (0.47) | SLC2A1PNMTADRB1TACR1ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | SLC2A1 301/4885PNMT 172/4885ADRB3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.